From professional translators, enterprises, web pages and freely available translation repositories.
56% vs.
among hbeag-positive patients, therapeutic response (63% vs 48%; p < 0.0001) and key secondary endpoints (mean log10 hbv dna reduction: -5.74 vs -4.42; p < 0.0001, pcr negativity: